#	Pagina
attuale pagina	/open-h2020/projects/220641/index.html

Opendata, web and dolomites

TOL2

An effective and safe targeted therapy for treatment of Myasthenia gravis

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TOL2 project word cloud

Explore the words cloud of the TOL2 project. It provides you a very rough idea of what is the project "TOL2" about.

iia investment weakness though therapy arms therapies utilize 14 streams muscles full immune considering upfront participation trials urgent progress innovative 257m everyday rare orphan moving frequently total causes complete unemployment 2029 remission 10 people tol2 chronic restricts look intrinsic myasthenic breathing autoimmune symptomatic drug company payments myasthenia body 20 swedish model expensive diseases pharma surpass patients calculated parts fda medical strategy mission skeletal induces tolerance 2021 life disease legs cure sight responsible global first power co clinical designation npv pharmaceutical treat royalties treatment wacc reducing business patient granted neuromuscular quality mg treatments death crises revenue gravis crisis toleranzia milestone 2019 sales

Project "TOL2" data sheet

The following table provides information about the project.

Coordinator	TOLERANZIA AB Organization address address: ERIK DAHLBERGSGATAN 11 A city: GOTEBORG postcode: 411 26 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	https://www.toleranzia.com/program/sme-instrument-phase-1-project/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-12-01 to 2019-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TOLERANZIA AB TOLERANZIA AB Organization address address: ERIK DAHLBERGSGATAN 11 A city: GOTEBORG postcode: 411 26 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (GOTEBORG)	coordinator	50˙000.00

Map

Project objective

Myasthenia gravis (MG) is a rare disease affecting 2/10.000 people. Although being a rare disease, MG is the most common chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs. MG restricts patients from having a full participation in everyday activities, frequently leading to unemployment and reducing their quality of life. Many patients may eventually experience a myasthenic crisis, the treatment of which is very expensive. Such crises can lead to the death of the patient. There is currently no cure for MG and neither is there any cure in sight. Even though there are over 30 MG-related clinical trials currently in progress, most of them are only symptomatic treatments.

Considering this urgent medical need, we are developing TOL2, an innovative therapy with potential to cure MG (not only symptomatic treatment). This will be the first therapy for MG that induces long-term remission. TOL2 is based on a tolerance-technology with potential to be developed for treatment of other autoimmune diseases. TOL2 has been granted Orphan Drug Designation by the US FDA.

Toleranzia is a Swedish pharmaceutical research and development company. Our therapies utilize the immune system’s own intrinsic power to treat autoimmune diseases. Our mission is to develop innovative therapies that will cure autoimmune diseases.

Our business strategy for TOL2 is to complete clinical phase IIa, and then to look for an agreement with a global pharma partner, who can or co-develop the therapy. Under this business model, revenue streams are obtained through upfront payments, milestone payments and royalties on product sales.

Considering total project cost of €5,6 m during years 2019-2021, upfront payments above €14 m and 20% royalties over sales, the NPV of the investment calculated (WACC 10%) will surpass €257m by 2029.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOL2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOL2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.